Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Nagel

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 1, 2013
An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approachChristine Petzoldt, Oliver Bley, Stephen J Byard, et al.
Pharmaceutical Research|August 2, 2017
Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical FormulationKlaus Gast, Anja Schüler, Martin Wolff, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 4, 2012
From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitorMartin Philipp Feth, Winfried Heyse, Bruno Baumgartner, et al.
Molecular Pharmaceutics|January 24, 2020
Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl ChainsMartin Wolff, Anja Schüler, Klaus Gast, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 16, 2010
Challenges in the development of hydrate phases as active pharmaceutical ingredients--an exampleMartin P Feth, Norbert Nagel, Bruno Baumgartner, et al.
Journal of Pharmaceutical Analysis|February 7, 2018
Enantiomeric characterization and structure elucidation of OtamixabanJian Shen, Jiping Yang, Winfried Heyse, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|October 1, 2013
An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approachChristine Petzoldt, Oliver Bley, Stephen J Byard, et al.
Pharmaceutical Research|August 2, 2017
Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical FormulationKlaus Gast, Anja Schüler, Martin Wolff, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 4, 2012
From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitorMartin Philipp Feth, Winfried Heyse, Bruno Baumgartner, et al.
Molecular Pharmaceutics|January 24, 2020
Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl ChainsMartin Wolff, Anja Schüler, Klaus Gast, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 16, 2010
Challenges in the development of hydrate phases as active pharmaceutical ingredients--an exampleMartin P Feth, Norbert Nagel, Bruno Baumgartner, et al.
Journal of Pharmaceutical Analysis|February 7, 2018
Enantiomeric characterization and structure elucidation of OtamixabanJian Shen, Jiping Yang, Winfried Heyse, et al.
Pageof 2